FDA
approval
· 2020-03-09
FDA Approved: EDARBYCLOR — Supplemental Application (Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals))
Summary
The FDA approved a supplemental application for EDARBYCLOR, a fixed-dose combination of azilsartan medoxomil and chlorthalidone, manufactured by Azurity Pharmac…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for EDARBYCLOR (AZILSARTAN KAMEDOXOMIL AND CHLORTHALIDONE)